Search

Your search keyword '"Yu, Chunjing"' showing total 173 results
Start Over Author "Yu, Chunjing"
173 results on '"Yu, Chunjing"'

21. A Light-Weight Context-Aware Self-Attention Model for Skin Lesion Segmentation

Author

Ma, Dongliang, Wu, Hao, Sun, Jun, Yu, Chunjing, Liu, Li, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Nayak, Abhaya C., editor, and Sharma, Alok, editor

Published
2019
Full Text
View/download PDF

23. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies

Author

He, Huihui, primary, Qi, Xiaowei, additional, Fu, Haitian, additional, Xu, Jianfeng, additional, Zheng, Qihuang, additional, Chen, Liping, additional, Zhang, Yu, additional, Hua, Haiying, additional, Xu, Wenhuan, additional, Xu, Zhenyu, additional, Chen, Xiaoping, additional, You, Qingjun, additional, Lin, Jianguo, additional, Huang, Gang, additional, Mao, Yong, additional, and Yu, Chunjing, additional

Published
2024
Full Text
View/download PDF

42. Diagnostic Performance of [18F]-Labeled PET/CT Tracers for Lymph Node/Bone Metastasis and Biochemical Recurrence Detection in Advanced Prostate Cancer: A Meta-Analysis.

Author

Guo, YiRui, Tian, Yu, Deng, Yuxin, Lu, ChunMei, Wang, YanJuan, and Yu, Chunjing

Subjects
BONE metastasis, LYMPH nodes, CANCER relapse, PROSTATE cancer, SENTINEL lymph nodes, POSITRON emission tomography
Abstract

Purpose: The aim of this study was to explore the diagnostic value of different fluorine-18 (18F)-labeled tracers for lymph node/bone metastasis and biochemical recurrence detection in advanced prostate cancer (PCa). Methods: PubMed, Embase, Web of Science, Cochrane databases, and the WHO International Clinical Trial Center were searched. The inclusion criteria were determined based on the Preferred Report Items of the Systematic Review and Meta-Analysis Guidelines. The Quality Assessment of Diagnostic Accuracy Studies-2 was used to assess the quality assessment of the included studies. The quantitative analysis of the included literature was performed on the patient and lesion basis, and the equivocal findings were considered negative or positive results, respectively. Results: Thirty-seven articles were included. On the patient basis, the pooled sensitivity and specificity of [18F]-labeled tracers were 0.80 (95% confidence interval [CI]: 0.78–0.83) and 0.89 (95% CI: 0.87–0.90) when equivocal results were considered to be positive and 0.80 (95% CI: 0.77–0.82) and 0.87 (95% CI: 0.85–0.89) when equivocal results were considered to be negative. On the lesion basis, the pooled sensitivity and specificity of [18F]-labeled tracers were 0.82 (95% CI: 0.80–0.83) and 0.91 (95% CI: 0.90–0.92) when equivocal lesions were regarded as positive and 0.81 (95% CI: 0.80–0.82) and 0.91 (95% CI: 0.90–0.92) when equivocal lesions were considered to be negative. Conclusion: [18F]-labeled tracers have high diagnostic efficacy for lymph node/bone metastasis and biochemical recurrence in advanced PCa. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results